Elinogrel
Elinogrel[edit | edit source]
Elinogrel is a pharmaceutical compound that functions as a platelet aggregation inhibitor. It is primarily studied for its potential use in preventing thrombosis and other cardiovascular events. Elinogrel is classified as a reversible P2Y12 receptor antagonist, which distinguishes it from other antiplatelet agents such as clopidogrel and prasugrel.
Mechanism of Action[edit | edit source]
Elinogrel works by selectively inhibiting the P2Y12 receptor, a key receptor involved in the activation of platelets. By blocking this receptor, elinogrel prevents the binding of adenosine diphosphate (ADP), a crucial step in the platelet activation process. This inhibition reduces platelet aggregation and thrombus formation, thereby decreasing the risk of myocardial infarction and stroke.
Pharmacokinetics[edit | edit source]
Elinogrel is administered both orally and intravenously, allowing for flexibility in clinical settings. The drug exhibits rapid onset of action, which is beneficial in acute situations where immediate platelet inhibition is required. Elinogrel is metabolized in the liver and excreted primarily through the kidneys.
Clinical Applications[edit | edit source]
Elinogrel has been investigated in various clinical trials for its efficacy in preventing thrombotic events in patients with acute coronary syndrome and those undergoing percutaneous coronary intervention (PCI). Its reversible nature and rapid onset make it a promising candidate for use in situations where quick platelet inhibition is necessary.
Side Effects[edit | edit source]
Common side effects of elinogrel include bleeding, headache, and nausea. As with other antiplatelet agents, there is an increased risk of bleeding complications, which necessitates careful monitoring of patients.
Development and Research[edit | edit source]
Elinogrel was developed as part of ongoing research to find more effective and safer antiplatelet therapies. Its development highlights the importance of targeting specific pathways in platelet activation to achieve desired therapeutic outcomes with minimal side effects.
Related Pages[edit | edit source]
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
|
WikiMD's Wellness Encyclopedia |
| Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD
